Market Research Logo

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Pipeline Review, H1 2016

Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Pipeline Review, H1 2016’, provides in depth analysis on Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted pipeline therapeutics.

The report provides comprehensive information on the Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)
  • The report reviews Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Overview
Therapeutics Development
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Products under Development by Stage of Development
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Products under Development by Therapy Area
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Products under Development by Indication
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Unknown Stage Products
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Products under Development by Companies
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Products under Development by Universities/Institutes
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Companies Involved in Therapeutics Development
Aduro BioTech, Inc.
Agenus, Inc.
Alligator Bioscience AB
AlphaMab Co., Ltd
CytomX Therapeutics, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
JHL Biotech, Inc.
Lytix Biopharma AS
Novartis AG
OncoImmune, Inc.
Pfizer Inc.
Premier Biomedical Inc.
PsiOxus Therapeutics Limited
Sutro Biopharma, Inc.
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Drug Profiles
ADC-1015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGEN-2041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anti-CTLA4 + LTX-315 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Antagonize CTLA4 for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics to Target CTLA4 and TNF Alpha - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JMW-3B3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KN-044 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugate to Target CTLA-4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize CTLA-4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize CTLA4 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target GLUT2 and CTLA4 for Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monocloncal Antibody to Inhibit CTLA-4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONC-392 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oncolytic Viruses to Antagonize CTLA4 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Dormant Projects
Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) - Featured News & Press Releases
Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate AGEN2041 at the American Association for Cancer Research (AACR) 2016 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Aduro BioTech, Inc., H1 2016
Pipeline by Agenus, Inc., H1 2016
Pipeline by Alligator Bioscience AB, H1 2016
Pipeline by AlphaMab Co., Ltd, H1 2016
Pipeline by CytomX Therapeutics, Inc., H1 2016
Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
Pipeline by JHL Biotech, Inc., H1 2016
Pipeline by Lytix Biopharma AS, H1 2016
Pipeline by Novartis AG, H1 2016
Pipeline by OncoImmune, Inc., H1 2016
Pipeline by Pfizer Inc., H1 2016
Pipeline by Premier Biomedical Inc., H1 2016
Pipeline by PsiOxus Therapeutics Limited, H1 2016
Pipeline by Sutro Biopharma, Inc., H1 2016
Dormant Projects, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report